iBio (IBIO) Amortizatization of Intangibles (2019 - 2025)
iBio (IBIO) posted quarterly Amortizatization of Intangibles of $9000.0 for Q3 2025, down 86.76% year-over-year from $68000.0 in Q3 2024, and down 96.68% quarter-over-quarter from $271000.0 in Q2 2025.
iBio (IBIO) Amortizatization of Intangibles (2019 - 2025) Analysis & Trends
iBio (IBIO) has reported Amortizatization of Intangibles for 7 consecutive years, with $9000.0 the latest figure, recorded in Q3 2025.
- In Q3 2025, Amortizatization of Intangibles fell 86.76% year-over-year to $9000.0; the TTM figure through Mar 2026 stood at $280000.0 (up 2.94% YoY), while the FY2025 annual figure was $271000.0, changed 0.0% from the prior year.
- Amortizatization of Intangibles slipped to $9000.0 in Q3 2025 per IBIO's latest filing, from $271000.0 in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $415000.0 in Q2 2021 and bottomed at -$275000.0 in Q2 2022.
- Historically, Amortizatization of Intangibles has averaged $80368.4 across 5 years, with a median of $68000.0 in 2023.
- Annual changes were most pronounced in 2022 — Amortizatization of Intangibles sank 166.27% — and 2024, when it soared 857.14%.
- iBio's Amortizatization of Intangibles stood at $93000.0 in 2021, then slumped by 72.04% to $26000.0 in 2022, then soared by 161.54% to $68000.0 in 2023, then changed by 0.0% to $68000.0 in 2024, then slumped by 86.76% to $9000.0 in 2025.
- Business Quant data shows IBIO's Amortizatization of Intangibles at $9000.0 in Q3 2025, $271000.0 in Q2 2025, and $68000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 678,000.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | iBio | 172.22 Mn | 172.22 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 9,000.00 |
| Sep 30, 2025 | 9,000.00 |
| Jun 30, 2025 | 271,000.00 |
| Jun 30, 2025 | 271,000.00 |
| Mar 31, 2025 | 68,000.00 |
| Mar 31, 2025 | 68,000.00 |
| Dec 31, 2024 | 68,000.00 |
| Dec 31, 2024 | 68,000.00 |
| Sep 30, 2024 | 68,000.00 |
| Sep 30, 2024 | 68,000.00 |
| Jun 30, 2024 | 68,000.00 |
| Jun 30, 2024 | 68,000.00 |
| Mar 31, 2024 | 67,000.00 |
| Mar 31, 2024 | 67,000.00 |
| Dec 31, 2023 | 68,000.00 |
| Dec 31, 2023 | 68,000.00 |
| Sep 30, 2023 | 68,000.00 |
| Sep 30, 2023 | 68,000.00 |
| Jun 30, 2023 | -89,000.00 |
| Jun 30, 2023 | -89,000.00 |